Nutriband Inc. (NASDAQ: NTRB) Price Target Raised to $15 Following AVERSA Fentanyl Manufacturing Milestone

Nutriband Inc. (NASDAQ: NTRB) has seen its price target raised to $15 by Noble Capital Markets' Senior Vice President and Equity Research Analyst, Robert LeBoyer, following the successful completion of commercial manufacturing and scale-up for its AVERSA Fentanyl abuse-deterrent transdermal patch. This development, achieved in partnership with Kindeva, represents a critical milestone for Nutriband, enabling the initiation of clinical supplies production and the submission of an Investigational New Drug (IND) application for a Phase 1 trial. The AVERSA program, utilizing the 505(b)(2) regulatory pathway, requires only a single Phase 1 study to demonstrate reduced appeal to recreational drug users, a step considered low risk by analysts.

LeBoyer has adjusted his FY2027 EPS forecast for Nutriband to $1.57, attributing this optimistic outlook to the company's adherence to projected timelines and the avoidance of an anticipated Q1 2025 equity raise. Sales are projected to commence in FY2027, with the New Drug Application (NDA) submission expected between late 2025 and early 2026. This progression underscores the potential of AVERSA technology to address the critical need for abuse-deterrent formulations in the pharmaceutical market, particularly for drugs with high abuse potential like fentanyl.